Industry Members
Novozymes offers a suite of recombinant proteins, growth factors, and biopolymers for cell-based therapeutic applications. Used as like-for-like replacements for serum derived proteins and in novel cell growth and delivery strategies, they overcome regulatory and production hurdles to bring your cell-based medical treatment to the clinic.
Animal-derived components carry the risk of contamination from prion-related TSE, viruses, and other adventitious organisms. Not only can these prove a risk to patient safety and cause delays in regulatory approval, but the inherent batch-to-batch inconsistency of animal-derived components can affect the performance of your cell-based therapy. Novozymes’ recombinant supplements provide a tertiary level of animal-free status, lowering your risk of potential contamination, improving regulatory compliance end-product safety.
Whether it is 1 milligram or 1 metric ton, Novozymes’ expertise in high-yield microbial expression systems can deliver high-quality components at any scale. Convenient packaging options and user-friendly formulations are available to streamline addition at all stages of your development pathway.
Contact: Tara Sharpe
Address:
Castle Court
59 Castle Boulevard
NG7 1FD
Nottingham
UK
Tel: +44 1158512409
Email:
tsrp@novozymes.com
